期刊
SCHIZOPHRENIA BULLETIN
卷 37, 期 2, 页码 300-305出版社
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbq059
关键词
schizophrenia; negative symptoms; rating scale
类别
资金
- Pfizer
- Organon
- AstraZeneca
- Wyeth
- Bristol Myers Squibb
- Cephalon
- Lilly
- Abbott
- Boehinger Ingelheim
- Solvay
- Sanofi Aventis
- Otsuka
- Lundbeck
- Novartis
- GlaxoSmithKline
The participants in the NIMH-MATRICS Consensus Development Conference on Negative Symptoms recommended that an instrument be developed that measured blunted affect, alogia, asociality, anhedonia, and avolition. The Brief Negative Symptom Scale (BNSS) is a 13-item instrument designed for clinical trials and other studies that measures these 5 domains. The interrater, test-retest, and internal consistency of the instrument were strong, with respective intraclass correlation coefficients of 0.93 for the BNSS total score and values of 0.89-0.95 for individual subscales. Comparisons with positive symptoms and other negative symptom instruments supported the discriminant and concurrent validity of the instrument.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据